References
- BatesGHarperPJonesLHuntington’s Disease3rd edOxfordOxford University Press2002
- The Huntington’s Disease Collaborative Research GroupA novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomesCell19937269719838458085
- LeonardDPKidsonMABrownJGA double blind trial of lithium carbonate and haloperidol in Huntington’s choreaAust N Z J Psychiatry197592115118125578
- BarrANFischerJHKollerWCSerum haloperidol concentration and choreiform movements in Huntington’s diseaseNeurology198838184882962009
- FrankSTetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington diseaseNeuropsychiatr Dis Treat2010665766520957126
- SchermanDJaudonPHenryJPCharacterization of the monoamine carrier of chromaffin granule membrane by binding of [2-3H]dihydrotetrabenazineProc Natl Acad Sci U S A1983805845886572908
- MehvarRJamaliFConcentration-effect relationships of tetrabenazine and dihydrotetrabenazine in the ratJ Pharm Sci1987764614653625491
- ThibautFFaucheuxBAMarquezJRegional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson’s disease: a postmortem study using tritated tetrabenazineBrain Res19956922332438548309
- LoginISCroninMJMacLeodRMTetrabenazine has properties of a dopamine receptor antagonistAnn Neurol1982122572627137960
- RechesABurkeREKuhnCMTetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brainJ Pharmacol Exp Ther19832255155216864517
- BurkeRERechesATraubMMTetrabenazine induces acute dystonic reactionsAnn Neurol1985172002023977303
- GauchRLehnerHThe metabolism of 2-chloro-11-(4-methyl-1-piperazinyl) dibenzo-(b,f)(1,4)-thiazepine (clotiapine). 3. The metabolism and excretion in the humanFarmaco Prat19692421001095780179
- Huntington Study GroupUnified Huntington’s disease rating scale: reliability and consistencyMov Disord1996111361428684382
- ShoulsonIHuntington’s disease: functional capacities in patients treated with neuroleptic and antidepressant drugsNeurology198131133313356125919
- Huntington Study GroupTetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trialNeurology200666336637216476934
- FrankSTetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD InvestigatorsBMC Neurol200996220021666
- FasanoACadedduFGuidubaldiAThe long-term effect of tetrabenazine in the management of Huntington diseaseClin Neuropharmacol200831631331819050408
- PaleacuDGiladiNMooreOTetrabenazine treatment in movement disordersClin Neuropharmacol20042723023315602104
- RossCATabriziSJHuntington’s disease: from molecular pathogenesis to clinical treatmentLancet Neurol2011101839821163446
- PoonLHKangGALeeAJRole of tetrabenazine for Huntington’s disease-associated choreaAnn Pharmacother20104461080108920442355
- BrusaLOrlacchioAMoschellaVTreatment of the symptoms of Huntington’s disease: preliminary results comparing aripiprazole and tetrabenazineMov Disord200924112612919170197
- GuayDRTetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disordersAm J Geriatr Pharmacother20108433137320869622
- TangTSChenXLiuJBezprozvannyIDopaminergic signaling and striatal neurodegeneration in Huntington’s diseaseJ Neurosci2007277899791017652581
- PaolettiPVilaIRifeMDopaminergic and glutamatergic signaling crosstalk in Huntington’s disease neurodegeneration: the role of p25/cyclin-dependent kinase 5J Neurosci200828100901010118829967
- WangHChenXLiYTetrabenazine is neuroprotective in Huntington’s disease miceMol Neurodegener20105183320420689